Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII
Researchers for Celgene say that they hit the primary endpoint for OPTIMISMM, a pivotal Phase III for treatment-resistant multiple myeloma that combined Pomalyst with bortezomib (Velcade) and low-dose dexamethasone compared to a combination of the last two alone.
The company is holding back the numbers for a scientific conference, but the company said that the study “achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for the pomalidomide arm versus the comparator arm.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.